New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export MRNA’s income statement to Excel — free account
Moderna, Inc.
MRNAModerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.
- Revenue
- +29.2%
- EPS
- n/m
- Free cash flow
- n/m
- Total debt
- +13,550.0%
Quarter to September 2026, against a year earlier
195.12
4.21
−2.11%
After hours trading: 199.30, up 2.14%, last trade Fri 7:57pm Eastern.
Follow MRNA
Alert me
Moderna, Inc. 10-Q filed Nov 6, 2026
Red flags
-
Short cash runway
Moderna, Inc.’s cash and short-term investments cover about 1.3 quarters of its operating cash burn
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Nov 6, 2025: no comparison — the Item was not found